NCT07929870
Effectiveness and Safety of Cellbooster Glow in Healthy Subjects
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Change from baseline recorded at visit 1 (Day -7 to Day 0) of epidermis hydration measured with Corneometer® at Day 42.
Timeframe: Day -7 to Day 0 and Day 42.
Secondary (18)
Change from baseline of epidermis hydration measured with Corneometer® at Day 70.
Proportion of participants having an improvement with CBG treatment as assessed by the investigator at Day 42 and Day 70, using the GAIS.
Degree of satisfaction of the injectors through the answers to a subjective evaluation questionnaire completed for each participant at Day 14.
Degree of satisfaction of the participants through the answers to a subjective evaluation questionnaire at Day 42 and Day 70.
Change from baseline of skin elasticity measured with Cutometer® at Day 42 and Day 70.
Show 13 moreShow less
Change from baseline of skin microcirculation measured with Laser Doppler at Day 42 and Day 70
Change from baseline of skin wrinkles measured with fringe projection system at Day 42 and Day 70.
Change from baseline of skin roughness measured with fringe projection system at Day 42 and Day 70
Illustration of the aesthetic effect with photos of the whole face (front face and profiles) with Colorface®.
Change from baseline in the skin color and homogeneity
Change from baseline in the multi pigment spot measured with Colorface®
Change from baseline in the contrast dark circle/ surrounding skin measured with Colorface®
Change from baseline in the pigmented dark circle measured with Colorface®
Change from baseline in the global redness inflammation (haemoglobin evaluation) measured with Colorface®
Change from baseline in gloss, and specular Gloss(GS)) measured with Colorface®
Evaluation of Injection Site Reactions (ISRs) by the investigator on the face, immediately after each injection session (Day 0, Day 14 and Day 28) and at Day 42 and Day 70.
Evaluation of Injection Site Reactions (ISRs) by the participant on the face during 2 weeks after each injection session.
Collection of adverse events (AEs) and concomitant treatments during the study.
Arms and interventions
CellBooster® Glow facial injectionExperimental
An initial injection session will be performed at visit 2 (D0). A second injection session will be performed at visit 3 (D14). And a third injection session will be performed at visit 4 (D28). CellBooster® Glow (CBG) Class III medical device Composition: * non-crosslinked Sodium Hyaluronate 18 mg * amino acids (Cysteine, Glutathione, Glycine, Lysine, Proline, Valine) * vitamins (Sodium Ascorbyl Phosphate, Biotin) * phosphate buffer pH 6.8-7.6 q.s
Devices: Injectable
Sites
2 sites in 1 country